Status:
COMPLETED
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds. Whether the two ...
Eligibility Criteria
Inclusion
- Diagnosis of metastatic breast cancer
- Able to visit the doctor's office at least every 14 days during the actual treatment
- Able to care for yourself, even if you cannot work or participate in other normal activities
- Your blood results must be adequate for therapy.
- If you are a female of childbearing potential and test negative for pregnancy, use a reliable method of birth control during and for three months following the last dose of study drug.
Exclusion
- Have received gemcitabine, paraplatin, or trastuzumab for your cancer.
- Be pregnant or breastfeeding
- Have cancer to the brain and has not been treated
- Have another active cancer besides breast cancer
- Have received stem cell or bone marrow transplant for hematologic (blood type) cancer
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00191451
Start Date
April 1 2004
End Date
October 1 2008
Last Update
November 20 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Indianapolis, Indiana, United States, 46203